![Peter Hawryluk](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Hawryluk
Director/Board Member at
Indianapolis Museum of Art, Inc.
Net worth: 75 M $ as of 31/08/2026
Profile
Peter Kent Hawryluk was the founder of Marcadia Biotech, Inc. (founded in 2005) where the title held was Vice President-Business Development & Finance.
Mr. Hawryluk was the founder of Avidity Biosciences, Inc. (founded in 2012) where the title held was Chief Business Officer.
Mr. Hawryluk was the founder of MBX Biosciences, Inc. (founded in 2018) where the title held was Director.
Current jobs include Board Member at Broad Daylight, Inc., Partner at Twilight Venture Partners LLC since 2003, and Member-Governance Board at Indianapolis Museum of Art, Inc. since 2013.
Former jobs include Chief Executive Officer & Director at MB2 LLC from 2014 to 2016, Managing Director at The Jordan Edmiston Group, Inc., Independent Director at Gemphire Therapeutics, Inc. from 2015 to 2019, Principal at Dow Jones & Co., Inc., Founding Partner at Presidio Partners, and Partner at JEGI Capital Management LLC.
Education includes graduate studies at Indiana University-Purdue University, an MBA from Kellogg School of Management, and an undergraduate degree from Princeton University conferred in 1990.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 06/05/2026 | 1,214,444 ( 2.52% ) | 75 M $ | 31/08/2026 |
Peter Hawryluk active positions
| Companies | Position | Start |
|---|---|---|
Twilight Venture Partners LLC
 Twilight Venture Partners LLC Investment ManagersFinance Twilight Venture Partners invests in companies located in the United States. The firm focuses on sectors such as biotechnology and medical technology. It participates in early stage capital transactions. It takes a seat on the board of directors. | Private Equity Investor | 01/01/2003 |
Broad Daylight, Inc.
 Broad Daylight, Inc. Packaged SoftwareTechnology Services Develops software for customer and employee self-service | Director/Board Member | - |
Indianapolis Museum of Art, Inc.
 Indianapolis Museum of Art, Inc. Other Consumer ServicesConsumer Services Operates an art museum | Director/Board Member | - |
Former positions of Peter Hawryluk
| Companies | Position | End |
|---|---|---|
| MBX BIOSCIENCES, INC. | Chief Executive Officer | 13/07/2026 |
| AVIDITY BIOSCIENCES, INC. | Founder | 01/12/2019 |
| METAVIA INC. | Director/Board Member | 28/02/2019 |
MB2 LLC
 MB2 LLC Pharmaceuticals: MajorHealth Technology Provides biopharmaceutical research services | Chief Executive Officer | 01/03/2016 |
JEGI Capital Management LLC
 JEGI Capital Management LLC Investment ManagersFinance JEGI Capital focuses exclusively on enabling technologies, infrastructure and support services companies that advance the role of communications, both within and beyond the business. They place special emphasis on technologies with potential impact on the media and marketing communications industries. JEGI Capital seeks technologies that help businesses operate more effectively, reach more customers, create closer links with existing customers or create new distribution channels. JEGI Capital invests in companies at various stages, ranging from the first institutional round, which follows the seed investment, to strategic rounds before IPOs. They expect an exit in three to five years. Typical investment size is between $1 million and $3 million, allowing for follow-on investments for a total investment of $5 million to $10 million per company over the total investment period. JEGI Capital prefers companies in either the late product development or early product deployment stage, but invests in more mature companies if there is a compelling strategic fit. The firm pursues investments that have several of the following key characteristics: experienced management team, a clear path to profitability, superior products or services, target market of $1 billion or more, competitive landscape and a scalable business model. | Corporate Officer/Principal | - |
Training of Peter Hawryluk
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
60
1st degree connections
15
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 15 |
|---|---|
Dow Jones & Co., Inc.
 Dow Jones & Co., Inc. Internet Software/ServicesTechnology Services Provides news and business information, delivering content to consumers and organizations | Technology Services |
Marcadia Biotech, Inc.
 Marcadia Biotech, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic products for diabetes and obesity | Health Technology |
Avidity Biosciences, Inc.
 Avidity Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that provides research and development, administrative & investment services | Health Technology |
MB2 LLC
MB2 LLC Pharmaceuticals: MajorHealth Technology Provides biopharmaceutical research services | Health Technology |
The Jordan Edmiston Group, Inc.
 The Jordan Edmiston Group, Inc. Miscellaneous Commercial ServicesCommercial Services JEGI was founded on the core belief that traditional media companies must embrace new technologies in order to evolve successfully into a network-based economy. In line with this philosophy, the firm is committed to investing in private companies with software, enabling technologies, infrastructure and support services relevant to traditional media, marketing communications and information businesses. The firm is focused on investing exclusively in enabling technologies, infrastructure and support services companies that advance the role of communications, both within and beyond the enterprise. Particular emphasis is placed on technologies with potential impact on the media and marketing communications industries. JEGI invests in companies at various stages, ranging from first institutional round to strategic rounds that precede IPOs. They prefer companies in either the late product development or early product deployment stage, but will invest in more mature companies if there is a compelling strategic fit. In general, JEGI pursues investments that have several of the following key characteristics: experienced management teams, clear path to profitability, superior products or services, competitive landscape and scalable business models. | Commercial Services |
Broad Daylight, Inc.
Broad Daylight, Inc. Packaged SoftwareTechnology Services Develops software for customer and employee self-service | Technology Services |
Twilight Venture Partners LLC
Twilight Venture Partners LLC Investment ManagersFinance Twilight Venture Partners invests in companies located in the United States. The firm focuses on sectors such as biotechnology and medical technology. It participates in early stage capital transactions. It takes a seat on the board of directors. | Finance |
Indiana University-Purdue University
 Indiana University-Purdue University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Presidio Partners
 Presidio Partners Investment ManagersFinance Presidio Partners invests in companies located in the United States. The firm targets companies operating in the fields of information technology, life sciences, and energy technology. It provides financing for early and late stage capital requirements. | Finance |
JEGI Capital Management LLC
JEGI Capital Management LLC Investment ManagersFinance JEGI Capital focuses exclusively on enabling technologies, infrastructure and support services companies that advance the role of communications, both within and beyond the business. They place special emphasis on technologies with potential impact on the media and marketing communications industries. JEGI Capital seeks technologies that help businesses operate more effectively, reach more customers, create closer links with existing customers or create new distribution channels. JEGI Capital invests in companies at various stages, ranging from the first institutional round, which follows the seed investment, to strategic rounds before IPOs. They expect an exit in three to five years. Typical investment size is between $1 million and $3 million, allowing for follow-on investments for a total investment of $5 million to $10 million per company over the total investment period. JEGI Capital prefers companies in either the late product development or early product deployment stage, but invests in more mature companies if there is a compelling strategic fit. The firm pursues investments that have several of the following key characteristics: experienced management team, a clear path to profitability, superior products or services, target market of $1 billion or more, competitive landscape and a scalable business model. | Finance |
Indianapolis Museum of Art, Inc.
Indianapolis Museum of Art, Inc. Other Consumer ServicesConsumer Services Operates an art museum | Consumer Services |
Kellogg School of Management
 Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gemphire Therapeutics, Inc.
 Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies for the treatment of Dyslipidemia | Health Technology |
MBX Biosciences, Inc.
 MBX Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company focused on discovery and development of novel precision peptide therapies for endocrine & metabolic disorders | Health Technology |
- Stock Market
- Insiders
- Peter Hawryluk
